The Microbot Medical Team

Who We Are

Management

Harel Gadot
CEO, President and Chairman

Simon Sharon
GM, Chief Technology Officer

Rachel Vaknin
Chief Financial Officer

Juan Diaz-Cartelle, MD
Chief Medical Officer

Earl Adamy
VP, Strategic Marketing & Business Development

Christina Bailey
VP, Sales

Eran Cohen
VP, Global Integration

Naama Moav
VP, Human Resources

Noa Ofer, PhD
VP, Quality Assurance and Regulatory Affairs

Allison Rosefort
VP, Marketing

Experienced Based

Board of Directors

Harel Gadot
CEO, President and Chairman

Martin J. Madden
Director

Scott Burell
Director

Aileen Stockburger
Director

P. Laxminarain
Director

Tal Wenderow
Director

David Wilson
Director

Harel Gadot

CEO, President and Chairman

Mr. Gadot is a co-founder of Microbot Medical and has been serving as the CEO since its inception and the Chairman of the Board since 2013. He is also the Chairman of XACTRobotics Ltd., another promising medical robotics company, specializing in the field of needle steering for medical procedures such as biopsies. Until 2013, Mr. Gadot was a board member at ConTIPI Ltd. Which was acquired in 2012 by Kimberly Clark. Prior to founding Microbot Medical, Mr. Gadot served as a Worldwide Group Marketing Director at Johnson & Johnson (Ethicon Inc., Somerville NJ), overseeing the company's global strategic marketing. Prior to this, he was the Regional Marketing Manager at Johnson & Johnson (Ethicon Inc., Paris, France), responsible for the strategic marketing for Europe, Middle East and Africa. During his tenure, both companies enjoyed continuous growth in revenues and new product launches. Prior to this, Harel held several management positions in marketing and sales at Johnson & Johnson Medical Israel. Mr. Gadot is a guest speaker for management and innovation courses at leading universities in the United States and Israel, and holds a Bachelor of Science (BS) from Siena College (USA) and a Master's in Business Administration (MBA) from Manchester University (UK).

Linkedin

Simon Sharon

GM, Chief Technology Officer

Mr. Sharon is a seasoned medical device executive with over 30 years of industry experience. Prior to rejoining Microbot, Simon served as the Chief Technology Officer at MEDX Xelerator, an Israel-based medical device and digital health incubator with partners such as Boston Scientific Corporation and Intellectual Ventures. He was also the Chairman of the Scientific Board at XACT Robotics, a private Israeli company developing a novel platform robotic technology for needle steering in minimally invasive interventional procedures. Prior to this, Mr. Sharon held the position of Chief Operating Officer at Microbot Medical Ltd. before it became a publicly traded company. Prior to joining Microbot in 2013, Mr. Sharon was the Vice President of Research & Development with IceCure Medical, a TASE traded company developing a portfolio of cryogenic ablation systems. Prior to IceCure, he held roles of increasing responsibility at Rockwell Automation–Anorad Israel Ltd, a leading linear motor-based, precision positioning equipment manufacturer. Prior to Rockwell, Simon was the Research & Development Manager at Disc-O-Tech Medical Technologies Ltd., a private orthopedic venture that was acquired by Kyphon (currently part of Medtronic), and before this was the Research & Development Manager at CI Systems, a worldwide supplier of a wide range of electro-optical test and measurement equipment.

Linkedin

Rachel Vaknin

Chief Financial Officer

Ms. Vaknin is a CPA licensed in the state of Israel. She has more than 20 years' experience in finance and operations. Prior to joining Microbot Medical, she was CFO for a company in the autonomous driving sector and some of her primary duties included budget planning and forecasts, preparation for financial due diligences and fundraising. From 2004 to 2016, she has held various finance roles of increasing importance for Mellanox Technologies Ltd., a multinational supplier of computer networking products based on InfiniBand and Ethernet technology, and prior to that she worked at BDO – Ziv & Haft, a leading worldwide accounting firm. Rachel holds a CPA and a BA in Economy and Accounting from Jerusalem Hebrew University.

Linkedin

Juan Diaz-Cartelle, MD

Chief Medical Officer

Dr. Juan Diaz-Cartelle leads the development and execution of the clinical strategy of the Company's technology platforms including LIBERTY products as well as its future pipeline. Dr. Diaz-Cartelle is an experienced medical device executive and a vascular surgeon. Prior to Microbot he served as Senior Medical Director for the Peripheral Interventions Division at Boston Scientific for 14 years where he oversaw, among other projects, the development of the drug eluting clinical program for peripheral vascular, acted as the medical liaison with global regulatory agencies, led the medical safety department and advised the division’s M&A group. Most recently he was the Executive Medical Director at Haemonetics, where he advised the company in new investments in the cardiovascular space and led the Medical Affairs department. Dr. Diaz-Cartelle obtained his medical degree at the University of Navarra (Spain) and completed his specialty in Angiology and Vascular Surgery at Hospital General Universitario Gregorio Maranon in Madrid (Spain).

Linkedin

Earl Adamy

VP, Strategic Marketing & Business Development

Mr. Adamy is a senior commercial leader with extensive experience introducing innovative medical technologies at both public and venture-backed companies. He has over 25 years of experience in commercial strategy, marketing, sales, and business development (M&A) at prominent companies including Johnson & Johnson, Olympus, Pacira, and XACT Robotics. At Johnson & Johnson, he served as Director of Global Strategic Marketing where he led the transformation of the company’s Biosurgery business, acquired new technologies, and led their global launch. At Olympus, he served as Executive Director of Marketing where he built a new commercial team dedicated to gastroenterology devices, launched several innovative new products, and oversaw strong double-digit revenue growth. Mr. Adamy holds a Bachelor of Science in Electrical Engineering from the Pennsylvania State University, and a Master of Business Administration from Rutgers Business School.

Linkedin

Christina Bailey

VP, Sales

Mrs. Bailey has held a variety of sales leadership roles. She has worked with notable companies like Boston Scientific, Abbott, Stryker and Intuitive Surgical that have equipped her with the insights necessary to drive growth and innovation. As the Vice President of US Sales at Endologix, her leadership in building and scaling the sales team while achieving sales milestones demonstrate her capability to lead crucial product launches. Ms. Bailey serves as a Board Member for USA Hockey. As a member of the U.S.A. Women’s Hockey Team, she won a gold medal at the 1998 Winter Olympics held in Nagano, Japan.

Linkedin

Eran Cohen

VP, Global Integration

Mr. Cohen is an accomplished healthcare executive and entrepreneur with deep expertise in the medical device sector, particularly in endovascular and robotic surgery. He has extensive experience in business development, strategic planning, and new product innovation across global markets. Eran has been with Microbot for over eight years and is among the inventors of the LIBERTY® Endovascular Robotic System. His background also includes leading business development at Accellta, expanding the company’s reach into emerging markets; marketing and business development roles at Estar Medical; and co-founding and managing ReproMed, a fertility-focused medical device venture. Eran Cohen holds a Bachelor of Science from the Hebrew University of Jerusalem and an MBA from the Technion – Israel Institute of Technology.

Linkedin

Naama Moav

VP, Human Resources

Mrs. Moav is a strategic HR leader with over 15 years of experience driving high-impact people strategies across global, high-growth organizations. Mrs. Moav specializes in organizational and operational design, translating business strategy into effective structures, processes, and team collaboration frameworks. Her expertise spans the full HR lifecycle, including talent acquisition, career development, performance management, and the implementation of scalable HR processes that strengthen organizational performance and employee engagement. Before joining Microbot Medical, Mrs. Moav served as Human Resources Manager at Paradox Security Systems. Prior to that, she held the role of Senior HR Specialist at ORBIT Communication Systems, a global leader in satellite communications.

Linkedin

Noa Ofer, PhD

VP, Quality Assurance and Regulatory Affairs

Ms. Ofer serves as Vice President of Quality Assurance and Regulatory Affairs, drawing on ten years of experience in the medical device field. Holding a PhD in biophysics and nanotechnology and licensed as an Israeli patent attorney, she brings a unique combination of scientific depth, regulatory insight, and strategic leadership. Noa is committed to creating a strong quality culture, supporting cross-functional teams, and guiding innovative technologies forward in a responsible and compliant manner.

Linkedin

Allison Rosefort

VP, Marketing

Ms. Rosefort has more than 20 years of experience in marketing, commercialization, and brand strategy within the medical device and healthcare technology industries. Prior to joining Microbot Medical, she served as Senior Director of Product Marketing and Commercialization at Topcon Healthcare, where she led cross-functional teams, managed global product launches, and contributed to the company’s rebranding and commercial growth across the Americas. Before that, she held product management roles at Integra LifeSciences and Byram Healthcare, where she oversaw product integrations, strategic marketing initiatives, and physician engagement programs that drove portfolio expansion and revenue growth. Prior to this, Allison was in Sales at ConvaTec, a Bristol Myers Squibb Company calling on hospitals, LTC facilities, SNFs, DMEs and home health agencies. Ms. Rosefort holds a BA from Tufts University and an MBA in Marketing from Fordham University’s Gabelli School of Business.

Linkedin

Martin J. Madden

Director

Mr. Madden has a deep and broad background in medical device innovation and new product development. During his thirty-year tenure with Johnson & Johnson's medical device organization, Martin was an innovator and research leader for nearly every medical device business including Cardiology, Electrophysiology, Peripheral Vascular Surgery, General and Colorectal Surgery, Aesthetics, Orthopaedics, Sports Medicine, Spine, and Trauma. As an Executive and a Vice-President of Johnson & Johnson, Martin served on the management boards of Johnson & Johnson's Global Surgery Group, Ethicon, Ethicon Endo-Surgery, DePuy-Synthes, and Cordis, with responsibility for research and development – inclusive of organic and licensed/acquired technology. Martin was also Chairman of J&J's Medical Device Research Council, with responsibility for talent strategy and technology acceleration. Martin's leadership experiences spanned internal start-ups, executing turn-around's, and leading large portfolio and technology intensive research organizations. Martin serves on Board of Directors and is an advisor to numerous medical device start-ups. Martin has an MBA from Columbia University, an MS in Mechanical Engineering from Carnegie-Mellon University, and a BS in Mechanical Engineering from the University of Dayton.

Linkedin

Scott Burell

Director

Since August 2018, Mr. Burell is the Chief Financial Officer of AIVITA Biomedical, Inc., an Irvine California-based immuno-oncology company focused on the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. From November 2006, Mr. Burell served as Chief Financial Officer, Secretary and Treasurer of CombiMatrix Corporation (NASDAQ: CBMX), a publicly traded diagnostics laboratory, until it was acquired by Invitae Corporation (NYSE: NVTA) in November 2017. Prior to this, Mr. Burell had served as CombiMatrix's Vice President of Finance and Controller since February 2001. From May 1999 to February 2001, Mr. Burell was the Controller for Network Commerce, Inc., (NASDAQ: SPNW), which was a publicly traded technology and information infrastructure company located in Seattle. Prior to this, Mr. Burell spent nine years with Arthur Andersen's Audit and Business Advisory practice in Seattle. During his tenure in public accounting, Mr. Burell worked with many clients, both public and private, in the high-tech and healthcare markets, and was involved in numerous public offerings, spin-offs, mergers and acquisitions. Mr. Burell obtained his Washington state CPA license in 1992 (currently inactive). He holds Bachelor of Science degrees in Accounting and Business Finance from Central Washington University.

Linkedin

Aileen Stockburger

Director

Aileen Stockburger is a highly accomplished strategic planning and corporate transaction executive. She has managed and closed sizable worldwide mergers and acquisitions, licensing agreements, and divestitures, with cumulative purchase prices in excess of $70 Billion. Ms. Stockburger had a distinguished career at Johnson & Johnson, where she held numerous business development and finance roles and served in various business areas. Aileen also served on several internal boards at Johnson & Johnson, including: J&J Worldwide Orthopaedics Group, J&J Comprehensive Care Group, Johnson's Baby Care Global Management Board, and J&J Development Corp. Most recently, Aileen was Worldwide Vice President of Business Development for the DePuy Synthes Group of Johnson & Johnson. Prior to DePuy Synthes, Ms. Stockburger coordinated and led the Business Development efforts for the Medical Devices & Diagnostics companies of Johnson & Johnson. She also spent 10 years as the Vice President of Worldwide Mergers and Acquisitions for the Johnson & Johnson Consumer Group. Before joining Johnson & Johnson, Aileen Stockburger spent several years at PriceWaterhouse Coopers, and earned her CPA certification. She received her MBA and BS from The Wharton School, University of Pennsylvania. Since retiring from J&J, Aileen has joined several boards: 2 public companies: Microbot Medical (NASDAQ:MBOT), Next Science (ASX:NXS), 2 private equity companies: Orchid Orthopaedic Solutions, Materna Medical, and one private family office technology company. Aileen also does M&A consulting and advising.

Linkedin

P. Laxminarain

Director

Mr. Laxminarain is a successful medical device executive with over 30 years' experience and proven track record. He is currently CEO of a South Florida based medtech startup Deinde Medical Corp., which is inventing devices for minimally invasive brain surgery. He is on the Board of GT Medical and Oculogica, both startups in the Neuro space. Prior to this, Mr Laxminarain served as Worldwide President of Codman Neurosurgery (a Johnson & Johnson company), which was acquired by Integra LifeSciences Holdings Corporation in October 2017 for approximately $1.045 billion. Mr. Laxminarain first joined Johnson & Johnson in 1986 where he held roles of increasing responsibility, including Worldwide President of Codman Neurosurgery from 2006 to 2017. In addition, Mr. Laxminarain held senior medical device positions in India, Singapore and South Korea. Mr. Laxminarain received an MBA from the Indian Institute of Management.

Linkedin

Tal Wenderow

Director

Mr. Wenderow is a Healthtech executive with a proven track record in bringing innovative & disruptive technologies to the healthcare market. Since September 2021, Mr. Wenderow serves as the Venture Partner at Genesis MedTech, a global medical device company. Previously, from February 2019, Mr. Wenderow served as the President and CEO of Vocalis Health Inc., an AI healthtech company pioneering the development of vocal biomarkers. Prior to Vocalis Health, Mr. Wenderow co-founded Corindus Vascular Robotics in 2002, which was a New York Stock Exchange listed company upon its acquisition by Siemens Healthineers in 2019 for $1.1B. Mr. Wenderow held various positions at Corindus from founder, Chief Executive Officer and director at inception, Executive Vice President Product & Business Development to his most recent role as Executive Vice President of International & Business Development. Mr. Wenderow holds a Bachelor of Science, Summa Cum Laude, in Mechanical Engineering from Technion in Israel and completed the Executive Program for Life Sciences at the Merage Foundation, Merage Business School, University of California, Irvine, CA, and has numerous patents issued based on his inventions.

Linkedin

David Wilson

Director

David J. Wilson is a proven business leader with more than 30 years of experience in senior leadership roles at medical technology companies. Mr. Wilson is currently the CEO of InnovHeart, an Italian based structural heart company focused on transcatheter mitral valve replacement. Previously, Mr. Wilson was President, Global Plasma at Haemonetics where he was responsible for expanding and strengthening the company's leadership market position in the plasma industry. Prior to that, he was WW President, Cordis, a Cardinal Health company. Mr. Wilson led the transition of the business from Johnson & Johnson into Cardinal Health focusing on revitalizing the product portfolio and business integration. Over a 20-year tenure at Johnson & Johnson, Mr. Wilson held positions of increasing responsibility driving sales, marketing, research and development, operations and business development. His senior leadership responsibilities included WW President, Mentor Corporation (aesthetic and reconstructive medicine), WWVP R&D Ethicon (Ethicon Inc, Ethicon Biosurgery, Women's Health and Urology, Acclarent (ENT) and Mentor), WWVP Ethicon Biosurgicals and WWVP R&D Cordis Endovascular. Prior to his career at Johnson & Johnson, Mr. Wilson was a biomedical engineer at Cohesion Corporation, a Bay Area start-up. Mr. Wilson received a Bachelor of Mechanical Engineering from Auburn University, a Master of Science in Biomedical Engineering from the University of Alabama at Birmingham, and an MBA from Columbia University. He holds numerous patents and currently serves on the Advisory Committee for the U.A.B. Department of Engineering. SHORTER VERSION: David J. Wilson's career spans over 30 years and includes broad, global leadership expertise in business strategy and operations, R&D, commercial readiness and product launches. He dedicated two decades in roles of increasing responsibility with various Johnson and Johnson (J&J) companies, including as the Worldwide President of Cordis. David held other leadership roles at J&J companies, namely Worldwide President of Mentor, Worldwide Vice President of Ethicon R&D and Vice President of Ethicon Biosurgicals. Prior to J&J, David was the President of Global Plasma at Haemonetics Corporation where he led the global commercialization of a next generation plasma collection system. David is currently the CEO of InnovHeart, an Italian based company focused on transcatheter mitral valve replacement. He is the holder of numerous medical device patents and has served as a Board member of several educational and healthcare institutions in the US. His education includes a Bachelor of Mechanical Engineering from Auburn University, a Master of Science in Biomedical Engineering from the University of Alabama at Birmingham and a Master of Business Administration from Columbia University

Linkedin